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ABSTRACT
Objective: To summarise how costs and health
benefits will change with the adoption of total
laparoscopic hysterectomy compared to total
abdominal hysterectomy for the treatment of early
stage endometrial cancer.
Design: Cost-effectiveness modelling using the
information from a randomised controlled trial.
Participants: Two hypothetical modelled cohorts of
1000 individuals undergoing total laparoscopic
hysterectomy and total abdominal hysterectomy.
Outcome measures: Surgery costs; hospital bed
days used; total healthcare costs; quality-adjusted life
years; and net monetary benefits.
Results: For 1000 individuals receiving total
laparoscopic hysterectomy surgery, the costs were
$509 575 higher, 3548 hospital fewer bed days were
used and total health services costs were reduced by
$3 746 221. There were 39.13 more quality-adjusted
life years for a 5 year period following surgery.
Conclusions: The adoption of total laparoscopic
hysterectomy is almost certainly a good decision for
health services policy makers. There is 100%
probability that it will be cost saving to health services,
a 86.8% probability that it will increase health benefits
and a 99.5% chance that it returns net monetary
benefits greater than zero.
INTRODUCTION
Endometrial cancer is the most common
gynaecological cancer accounting for
300 000 new diagnoses worldwide.1 In devel-
oped countries, lifetime risk is between 2.5%
and 3% and incidence is rising.2 3 Risk
factors include increasing age, obesity, dia-
betes mellitus, nulliparity, late menopause,
unopposed oestrogen intake or oestrogen
producing tumours, a history of breast
cancer and use of tamoxifen.4 5 Standard
treatment is surgery to remove the uterus,
fallopian tubes and ovaries. In selected
patients, retroperitoneal pelvic and/or aortic
lymph nodes are removed to establish the
extent of the cancer and assist in ongoing
treatment choices. Total laparoscopic hyster-
ectomy (TLH) has been proposed as an
alternative to total abdominal hysterectomy
(TAH) widely used by gynaecological cancer
surgeons and has been tested in three rando-
mised trials worldwide. Patients who had
TLH instead of TAH for uterine cancer had
better postsurgical quality of life (QoL),
fewer complications and shorter hospital
stay.6–8 One study did show an incidence of
major and minor surgical complications as
similar in patients undergoing a TLH or
TAH.9 The aim of the research reported
ARTICLE SUMMARY
Article focus
▪ To evaluate how costs and health benefits
change with the adoption of laproscopic surgery
rather than using laparotomy to treat endometrial
cancer.
Key messages
▪ Surgery costs are higher for laproscopic surgery.
▪ Length of stay in hospital and overall health
services costs are lower for laproscopic surgery.
▪ Health benefits measured by quality-adjusted life
years are higher for laproscopic surgery.
Strengths and limitations of this study
▪ Lower cost and better health outcomes are a
‘win win’ for health services.
▪ The conclusions are easy to interpret for health
policy makers.
▪ Mortality data were used from a study carried
out in a different jurisdiction.
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here is to identify how costs and health benefits will
change with the adoption of TLH over TAH through
laparotomy for the treatment of early stage endometrial
cancer. A health services perspective is adopted and
quality-adjusted life years (QALYs) estimated.
Information for this modelling study was available from
the LACE trial.10
METHOD
Randomised controlled trial
The LACE trial is registered with clinicaltrials.gov
(NCT00096408) and the Australian New Zealand
Clinical Trials Registry (CTRN12606000261516) and was
approved by all relevant hospital and university human
research ethics committees. A detailed description of
the study including details of the two surgical
approaches has been published previously.6 10 Between
October 2005 and June 2010, 760 patients were
recruited through 1 of the 20 participating tertiary
gynaecological oncology centres in Australia, New
Zealand, Hong Kong and Scotland. Women were eligible
if they were aged 18 years or older, with histologically
confirmed endometrioid adenocarcinoma of the endo-
metrium of any FIGO grade, and had an Eastern
Cooperative Oncology Group (ECOG) score of less than
2. Further inclusion criteria included imaging studies
suggesting the absence of extra-uterine disease. Patients
were excluded from the study if any of the following
criteria were met: histological cell-type other than endo-
metrioid on curettage, clinically advanced disease (stage
II–IV) or bulky lymph nodes on imaging, uterine size
greater than 10 weeks of gestation, estimated life expect-
ancy of less than 6 months, medically unfit for surgery,
patient compliance or geographic proximity preventing
adequate follow-up or unfit to complete QoL question-
naires. The FIGO criteria for stage (2009) were used.
Randomisation using stratified permuted blocks was
carried out centrally and independent from other study
procedures through a web-based system at the University
of Queensland. Randomisation was stratified according
to treating centre and by grade of differentiation as
taken from the endometrial biopsy/D&C.6 10 All sur-
geons on the trial had to be accredited by the trial man-
agement committee before being eligible to enrol
patients. After informed consent was obtained, trial staff
checked eligibility and received notification of the allo-
cated treatment via the web-based case report system.
Blinding was not possible due to ethical considerations
and the nature of the treatment.
Primary outcomes from the LACE trial have been pub-
lished6 11 and show the TLH and TAH groups were
similar according to clinical and demographic factors
and the incidence of intra-operative adverse events were
comparable. The incidence of postoperative adverse
events and serious adverse events was significantly
higher in the TAH group compared to the TLH group.
There were differences in the rates of lymph node
dissection with 60.2% in the TAH group and 39.9% in
the TLH group and this may influence adverse events
and costs and the QoL outcomes. The average operating
time was higher for TLH (132 min) as compared to
TAH (107 min), but the median length of stay was lower
for TLH (2 days) as compared to TAH (5 days). QoL
outcomes were published for a subset of the participants
and it show that in the early phase of recovery the TLH
group had better QoL from baseline compared to the
TAH group in all subscales of the Functional Assessment
of Cancer Therapy-General (FACT-G) V.4, except for
emotional and social wellbeing. Some QoL advantages
were still present up to 6 months after surgery.
Cost-effectiveness analysis
A two-state Markov model was used to predict how a gen-
eralised population of patients transitioned into a state
of DEAD from ALIVE for a modelled cohort of 1000
TAH and TLH patients during the 1825 days or 5 years
postsurgery. Daily risks of death were estimated for
either arm of the trial and applied to the two cohorts
based on survival data reported by Walker et al.12 This
was a separate study of mortality risk from laparoscopy
versus laparotomy for comprehensive surgical staging of
uterine cancer and it revealed 5-year survival of 89.8%
for patients randomly assigned to laparoscopy and
89.8% for patients randomly assigned to laparotomy. For
each day of the model, a utility score was assigned to
those in the ALIVE state based on the individual EQ-5D
tariffs reported from trial participants. Values were col-
lected presurgery and 1 week, 4 weeks, 3 months and
6 months postsurgery. The 6-month value was used for
all days from 6 to 12 months. After 12 months, it was
assumed that the QoL was similar for both groups and a
mean score was used until day 1825. Health benefits
arising in future time periods were discounted at 3% in
line with recent guidelines. The costs of the two surgical
treatments included theatre nursing costs, allocated by
duration of procedure; all equipment and consumables
used; and Medicare Benefits Schedule13 items for surgi-
cal and anaesthetics fees for abdominal and laparo-
scopic procedures. The costs of health services used in
the 6 months following surgery were consultations with
doctors other than gynaecology oncology; psychiatrist,
psychologist or other mental health counsellors; nurse
practitioner; home health nurse and physical/occupa-
tional or respiratory therapist; and consultations as an
outpatient and visits to the emergency department. The
number of days in hospital recovering from the initial
surgical treatment and any subsequent admissions
during the 6 months after treatment were aggregated
and valued by a national hospital pricing model14; these
prices were adjusted to 2011 values based on 3% annual
price inflation. All costs were valued in Australian dollars
at 2011 prices, health benefits represented by QALYs
and the marginal QALY was given a monetary value of
$64 000.15 Net monetary benefits were estimated by
multiplying each QALY gained by $64 000 and then
2 Graves N, Janda M, Merollini K, et al.. BMJ Open 2013;3:e001884. doi:10.1136/bmjopen-2012-001884
Treatment of early stage endometrial cancer
 group.bmj.com on July 15, 2014 - Published by bmjopen.bmj.comDownloaded from 
deducting the change to costs. Uncertainty among the
model parameters was included by fitting the individual
data to probability distributions. The β-distribution was
used for transition probabilities and utility scores, and
the γ-distribution was used for the costs.16 One thousand
random samples were taken from the prior distributions
to reveal the joint distribution of cost and QALY out-
comes for patients in both arms of the trial.
Because of different rates of lymph node dissection
among the two groups, an alternate version of the
model that excluded all patients with lymph node dissec-
tion was also evaluated. This scenario analysis will assess
the sensitivity of the conclusions to any bias on out-
comes arising from the differences in rates of lymph
node dissection.
RESULTS
The mean and SD for the EQ-5D scores for TAH and
TLH for 1 week, 4 weeks, 3 months and 6 months post-
surgery are shown in table 1. The difference in QoL out-
comes is modest, but is the largest in 1 week postsurgery
and then reduces over time.
The costs of theatre time, equipment and consumables
were provided by the Royal Brisbane and Women’s
Hospital and were $1734.49 for a TLH case and $957.42
for a TAH case. Medicare Benefits Schedule item
numbers (http://www.mbsonline.gov.au/) were used to
estimate the costs of surgeon and anaesthetists time and
in total were $5610 for TLH and $5460 for TAH. Nursing
costs of $46.22/h were used to reflect a Grade 6 Nurse
and it was assumed that 2.5 nurses are required to
support either a TLH or TAH. The duration of each
surgery was used to estimate nursing costs per case. One
hour of nursing time was added for preparation and
clean up. Medicare Benefits Schedule item numbers
were also used to value the subsequent use of consulta-
tions with GPs ($120.3), consultations with psychiatrist,
psychologist or other mental health counsellors ($249.3),
visits to the emergency department ($200.95), short con-
sultations with nurse practitioner, home health nurse,
physical/occupational or respiratory therapist ($22.7)
and visits to a hospital out-patient department ($200.95).
The cost of a night in a hospital bed was valued at $1133;
this was derived by adjusting estimates published by
Australian Institute of Health & Welfare to 2011 prices.14
The most useful results from the modelling that com-
pared TLH with TAH are shown in table 2.
On average, the higher surgery costs of TLH over
TAH are compensated by cost savings in health services
that accrue in the 6 months after surgery. In particular
3.55 hospital bed days are saved for each patient who
has TLH, and there are extrahealth benefits of 0.04
QALYs that accrue during the 1825 days of model dur-
ation. The uncertainty in the data is shown by figure 1,
which illustrates the joint distribution of change to costs
and health benefits from a decision to adopt TLH over
TAH. The distributions of the total cost and QALY out-
comes are shown in online supplementary appendix 1.
The adoption of TLH over TAH will always save costs
and there is 86.8% probability that health benefits will
be increased, which means a high chance of health ser-
vices enjoying a ‘win win’. The distribution of the net
monetary benefit of a decision to adopt TLH over TAH
is shown in figure 2 and there is a 99.5% probability that
the net monetary benefit from adoption TLH over TAH
will be greater than zero. The area to the left of the
dashed line at zero in figure 2 is 0.05% of the area
under this curve.
Model results did change when the patients with
lymph-node dissection were excluded: the difference in
surgery costs fell from $510 to $482, the savings in
lengths of stay fell from 3.55 to 3.38, total cost savings
fell from $3746 to $3734 and QALY gains were reduced
from 0.04 to 0.03. Under this scenario, the adoption of
TLH over TAH will again always save costs and there is
79.8% probability that health benefits will be increased.
There is a 98.3% probability that the net monetary
benefit from adoption TLH over TAH will be greater
than zero, providing strong evidence that adoption is a
good decision.
DISCUSSION
Based on the data, we have used the adoption of TLH
which is almost certainly a good decision for health ser-
vices policy makers. There is 100% probability that it will
be cost saving to health services, a 86.8% probability that
it will increase health benefits, although the QoL bene-
fits are modest for the average individual, and a 99.5%
chance that it returns net monetary benefits that are
greater than zero. Our findings are in line with previous
reports from the literature. A Dutch study by Bijen et al17
also reported higher costs for TLH offset by a shorter
hospital stay. Within the 3-month follow-up period, the
QoL outcomes were similar between the two treatments.
Further analysis of trial data found TLH cost-effective
for patients >70 years of age, but not for very obese
patients with body mass index > 35.18 In another clinical
trial of hysterectomy for benign diagnoses, Garry et al19
not only reported higher complication rates for LH but
also confirmed a shorter hospital stay and faster post-
operative recovery compared to TAH. Sculpher et al20
found higher costs of laparoscopic hysterectomy com-
pared to abdominal hysterectomy (£186) with similar
QALYs resulting in incremental costs of £26 571 for each
Table 1 EQ-5D scores from all trial participants
TAH (mean (SD)) TLH (Mean (SD))
1 week 0.63 (0.24) 0.71 (0.23)
4 weeks 0.79 (0.22) 0.84 (0.19)
3 months 0.82 (0.25) 0.86 (0.22)
6 months 0.82 (0.27) 0.86 (0.23)
TAH, total abdominal hysterectomy; TLH, total laparoscopic
hysterectomy.
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QALY gained. There was only a 56% probability that lap-
aroscopic hysterectomy is cost-effective. It should be
noted that health outcomes were not measured before
or immediately after the procedure, but merely 6 weeks
later which may underestimate true health benefits and
hence understate the overall cost-effectiveness. The dif-
ferences in hospital length of stay between the treat-
ments were also small in this trial. A large difference of
3.55 days found in our data (table 1) was the main
driver of cost savings.
Studies from the USA,21 Australia,22 France23 and the
UK24 found costs of TAH and TLH to be similar or not
significantly different and consistently reported a signifi-
cantly shorter hospital stay for TLH. A recent cost com-
parison of different treatment approaches for
endometrial cancer found TLH to be the least expensive
alternative with costs ranging from US$6581–US$10 128
compared to US$7009–US$12 847 for TAH, depending
on the range of costs included in the analysis.25 In con-
trast, a study by Lumsden et al26 with randomised
Scottish patients reported higher overall costs for LH
due to higher operation costs which were not compen-
sated by the decreased length of stay or similar QoL out-
comes. They concluded that LH is unlikely to be
cost-effective in the National Health Services (NHS)
context. Similarly, a large cross-sectional analysis by
Campbell et al27 associated TLH with higher hospital
costs. This was confirmed by Lenihan et al,28 but they
also noted decreased indirect costs to employers due to
a faster recovery and fewer hours at work lost.
Although cost estimates may vary due to different
patient populations, perspectives, surgical and measure-
ment techniques, the majority of recently published lit-
erature favours TLH over TAH economically.29 We
believe that our findings derived from the large multi-
centre LACE trial represent an accurate estimate of out-
comes. The use of TLH is recommended although
decisions on the technique employed should be based
on individual patient circumstances, including age and
comorbidities. Future studies could look at long-term
effects from a societal perspective. The data from Walker
et al12 were used to show mortality risks for the two com-
peting treatments. The reasons for this are their data
were complete for a 5-year period and were audited with
all follow-up-consistent and survival status obtained for
each patient at the time of database lock, this is not the
case for the LACE mortality outcomes; their publication
has be reviewed by referees, statistical methods have
been independently agreed upon and as such the sur-
vival curves for both groups reflect the scientific design
for a non-inferiority equivalence design, this is yet to be
achieved for the LACE trial.
Our data show that TLH is a safe and cost-effective
treatment approach for early endometrial cancer and is
Figure 1 Joint distribution of change to costs and health
benefits from a decision to adopt total laparoscopic
hysterectomy (TLH) over total abdominal hysterectomy (TAH).
Figure 2 Distribution of the net monetary benefit of a
decision to adopt adopt total laparoscopic hysterectomy (TLH)
over total abdominal hysterectomy (TAH).
Table 2 Results from cost-effectiveness model
TAH (mean (SD)) TLH (mean (SD)) Difference per patient Difference for 1000 patients
Surgery costs ($) 6755 (4.76) 7265 (3.93) 510 509575.37
Bed days used* 7.31 (0.52) 3.76 (0.24) −3.55 −3548.18
Total costs ($)† 15870 (637) 12124 (311) −3746 −3746221.69
QALYs‡ 3.42 (0.046) 3.46 (0.039) 0.04 39.13
*For the recovery from surgery and for subsequent admissions within 6 months.
†This includes all health services used from surgery to 6 months after.
‡For the 1825 days described by the model.
TAH, total abdominal hysterectomy; TLH, total laparoscopic hysterectomy.
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likely to improve patients’ health outcomes whilst saving
healthcare resources. The main drivers of the cost
savings are reduced length of stay and reduced compli-
cations. Data from LACE11 however show complications
were 14.3% for TAH and 8.2% in TLH, operating time
was lower (132 vs 107 min) and length of stay in hospital
was reduced from 5 to 2 days. Another recent study from
the USA7 showed TLH had fewer moderate to severe
postoperative adverse events (14% vs 21%), similar rates
of intraoperative complications, but the length of hos-
pital say was reduced by 2 days. To date, hysterectomy
remains the most common major gynaecological surgical
procedure, but the uptake of TLH amongst gynaeco-
logical surgeons has been slow. Further research might
examine how a minimally invasive surgical approach can
be established in real, day-to-day clinical practice to the
benefit of women and their communities.
Acknowledgements We are grateful to the Gynecologic Oncology Group
(GOG) for sharing their data on a 5-year mortality risk for laparotomy and
laparoscopy patients. We thank all the women and all surgeons who
participated in the LACE trial. We thank the LACE trial safety committee
members Alex Crandon, Neville Hacker, Paul Vasey, and Alison Hadley and
Peta Forder for providing trial methods expertise. We are grateful to all
patients whose participation made this study possible.
Contributors NG, MJ, KM, VG and AO all conceived the idea of the study and
were responsible for the design of the study. NG and KM were responsible for
undertaking the data analysis and produced the tables and graphs. MJ, VG
and AO provided input into the data analysis. The initial draft of the
manuscript was prepared by NG and KM and then circulated repeatedly
among all authors for critical revision. AO was responsible for the acquisition
of the data and all authors contributed to the interpretation of the results. All
authors read and approved the final manuscript.
Funding The LACE trial was funded by Cancer Council Queensland, Cancer
Council New South Wales, Cancer Council Victoria, Cancer Council Western
Australia; NHMRC project grant 456110; Cancer Australia project grant 631523;
the Women and Infants Research Foundation, Western Australia; Royal Brisbane
and Women’s Hospital Foundation; Wesley Research Institute; Gallipoli Research
Foundation; Gynetech; TYCO Healthcare, Australia; Johnson and Johnson
Medical, Australia; Hunter New England Centre for Gynaecological Cancer;
Genesis Oncology Trust; and Smart Health Research Grant/QLD Health. MJ is
supported by a National Health and Medical Research Council Career
Development Award 1045247. The investigators also acknowledge the support of
the Australian Gynaecological Endoscopy Society (AGES) to specifically conduct
the cost-effectiveness analysis.
Competing interests None.
Ethics approval This is a modeling study, using existing data only.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
REFERENCES
1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer
Incidence and Mortality Worldwide. Lyon, France: IARC CancerBase
No. 10 [Internet]. ed. I.A.f.R.o. Cancer, 2010.
2. Jemal A, Murray T, Ward E. Cancer statistics. CA Cancer J Clin
2005;55:10–30.
3. AIHW, Cancer in Australia. Cancer series number 28. Canberra:
AIHW, 2001.
4. Hacker NF. Uterine cancer. In: Berek JS, eds. Practical gynecologic
oncology. Philadelphia: Lippincott Williams and Wilkins, 2000: 341–87.
5. Morrow CP, Curtin JP. Synopsis of gynecologic oncology. New York:
Churchill Livingstone, 1998.
6. Janda M, Gebski V, Brand A, et al. Quality of life after total
laparoscopic hysterectomy versus total abdominal hysterectomy for
stage I endometrial cancer (LACE): a randomised trial. Lancet Oncol
2010;11:772–80.
7. Walker JL. Laparoscopy compared with laparotomy for
comprehensive surgical staging of uterine cancer: Gynecologic
Oncology Group Study LAP2. J Clin Oncol 2009;27:
5331–6.
8. Kornblith AB. Quality of life of patients with endometrial cancer
undergoing laparoscopic international federation of gynecology and
obstetrics staging compared with laparotomy: a Gynecologic
Oncology Group study. J Clin Oncol 2009;27:5337–42.
9. Mourits MJ, Bijen CB, Arts HJ, et al. Safety of laparoscopy versus
laparotomy in early-stage endometrial cancer: a randomised trial. Lancet
Oncol 2010;11:763–71.
10. Janda M, Gebski V, Forder P, et al. Total laparoscopic versus open
surgery for stage 1 endometrial cancer: the LACE randomized
controlled trial. Contemp Clin Trials 2006;27:353–63.
11. Obermair A, Janda M, Baker J, et al. Improved surgical safety after
laparoscopic compared to open surgery for apparent early stage
endometrial cancer: results from a randomised controlled trial. Eur J
Cancer 2012;48:1147–53.
12. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and
survival after random assignment to laparoscopy versus laparotomy
for comprehensive surgical staging of uterine cancer: Gynecologic
Oncology Group LAP2 Study. J Clin Oncol 2012;30:695–700.
13. The Australian Government—Department of Health and Ageing.
Medicare Benefits Schedule Book, edn. Canberra: Department of
Health and Ageing, 2010.
14. Australian Institute of Health & Welfare. Australian Hospital Statistics
2005–06. Canberra: Australian Institute of Health & Welfare, 2007.
15. Shiroiwa T, Sung YK, Fukuda T, et al. International survey on
willingness-to-pay (WTP) for one additional QALY gained: what is
the threshold of cost effectiveness? Health Econ 2010;19:422–37.
16. Briggs A, Claxton K, Sculpher M. Decision modelling for health
economic evaluation. Oxford: Oxford University Press, 2006.
17. Bijen CB, Vermeulen KM, Mourits MJ, et al. Cost effectiveness of
laparoscopy versus laparotomy in early stage endometrial cancer:
a randomised trial. Gynecol Oncol 2011;121:76–82.
18. Bijen CB, et al. Laparoscopic hysterectomy is preferred over
laparotomy in early endometrial cancer patients, however not cost
effective in the very obese. Eur J Cancer 2011;47:2158–65.
19. Garry R, Fountain J, Brown J, et al. EVALUATE hysterectomy trial:
a multicentre randomised trial comparing abdominal, vaginal and
laparoscopic methods of hysterectomy. Health Technol Assess
2004;8:1–154.
20. Sculpher M, Manca A, Abbott J, et al. Cost effectiveness analysis of
laparoscopic hysterectomy compared with standard hysterectomy:
results from a randomised trial. BMJ 2004;328:134.
21. Abdelmonem A, Wilson H, Pasic R. Observational comparison of
abdominal, vaginal and laparoscopic hysterectomy as performed at
a university teaching hospital. J Reprod Med 2006;51:945–54.
22. Tsaltas J, Magnus A, Mamers PM, et al. Laparoscopic and
abdominal hysterectomy: a cost comparison. Med J Aust
1997;166:205–7.
23. Chapron C, Fernandez B, Dubuisson JB. Total hysterectomy for
benign pathologies: direct costs comparison between laparoscopic
and abdominal hysterectomy. Eur J Obstet Gynecol Reprod Biol
2000;89:141–7.
24. Simon NV, Laveran RL, Cavanaugh S, et al. Laparoscopic
supracervical hysterectomy vs. abdominal hysterectomy in a
community hospital. A cost comparison. J Reprod Med
1999;44:339–45.
25. Barnett JC, Judd JP, Wu JM, et al. Cost comparison among robotic,
laparoscopic, and open hysterectomy for endometrial cancer. Obstet
Gynecol 2010;116:685–93.
26. Lumsden MA, Twaddle S, Hawthorn R, et al. A randomised
comparison and economic evaluation of laparoscopic-assisted
hysterectomy and abdominal hysterectomy. BJOG
2000;107:1386–91.
27. Campbell ES, Xiao H, Smith MK. Types of hysterectomy.
Comparison of characteristics, hospital costs, utilization and
outcomes. J Reprod Med 2003;48:943–9.
28. Lenihan JP Jr, Kovanda C, Cammarano C. Comparison of
laparoscopic-assisted vaginal hysterectomy with traditional
hysterectomy for cost-effectiveness to employers. Am J Obstet
Gynecol 2004;190:1714–20.; discussion 1720–2.
29. Hauspy J, Jiménez W, Rosen B, et al. Laparoscopic surgery for
endometrial cancer: a review. J Obstet Gynaecol Can
2010;32:570–9.
Graves N, Janda M, Merollini K, et al.. BMJ Open 2013;3:e001884. doi:10.1136/bmjopen-2012-001884 5
Treatment of early stage endometrial cancer
 group.bmj.com on July 15, 2014 - Published by bmjopen.bmj.comDownloaded from 
doi: 10.1136/bmjopen-2012-001884
 2013 3: BMJ Open
 
Nicholas Graves, Monika Janda, Katharina Merollini, et al.
 
stage endometrial cancer
hysterectomy for the treatment of early
hysterectomy compared to total abdominal 
The cost-effectiveness of total laparoscopic
 http://bmjopen.bmj.com/content/3/4/e001884.full.html
Updated information and services can be found at: 
These include:
Data Supplement
 http://bmjopen.bmj.com/content/suppl/2013/04/18/bmjopen-2012-001884.DC1.html
"Supplementary Data"
References
 http://bmjopen.bmj.com/content/3/4/e001884.full.html#ref-list-1
This article cites 22 articles, 4 of which can be accessed free at:
Open Access
http://creativecommons.org/licenses/by-nc/3.0/legalcode
http://creativecommons.org/licenses/by-nc/3.0/ and 
compliance with the license. See:
work is properly cited, the use is non commercial and is otherwise in 
use, distribution, and reproduction in any medium, provided the original
Creative Commons Attribution Non-commercial License, which permits 
This is an open-access article distributed under the terms of the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (126 articles)Surgery   
 (107 articles)Health economics   
 
Articles on similar topics can be found in the following collections
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on July 15, 2014 - Published by bmjopen.bmj.comDownloaded from 
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on July 15, 2014 - Published by bmjopen.bmj.comDownloaded from 
